Neuroimaging Core

核心F：网卡摘要/摘要 PIT-ADRC的总体目标是开展和促进研究，以增加我们的 了解：1)阿尔茨海默病(AD)的病因和发病机制，2)发病机制 阿尔茨海默病的认知和行为症状，以及3)制定早期有效的策略 阿尔茨海默病及相关痴呆的诊断和治疗。神经成像核心(NIC)将支持这些 通过开发和应用尖端神经成像技术来实现中心范围内的目标 重点关注AD谱系的早期和症状前阶段。 随着对临床前生物标记物的研究继续进行，越来越清楚的是，功能性和 结构脑成像数据可能是识别AD先证者最早病理表现的关键 任何有意义的临床变化。NIC将继续开发和分发技术，以获取和 解释脑功能和结构成像数据，以支持AD研究。网络接口卡将推进 该中心的目标是支持和促进研究，以增加我们对病因和 阿尔茨海默病的发病机制，有助于开发新的治疗方法和监测治疗方法 功效。NIC维护通过临床核心登记的个人的结构成像数据集， 我们继续致力于尖端分析技术的扩展，以及新型放射性示踪剂配体 用正电子发射断层扫描(PET)(即PIB、AV-1451和GTP-1)测量。 NIC的工作将加快努力，通过识别 成像生物标志物，以监测疾病的自然和治疗历史。精心策划的“准备受审” 参与者数据库将允许PIT-ADRC的研究人员跟踪基于生物标记物的临床进展，并 确定风险和保护因素。该数据库还将独特地定位PIT-ADRC，以确定潜在的 参与者根据特定的生物标记物特征。最后，NIC对质量保证的关注将 确保神经成像方法生成的数据测量它们声称要测量的内容，并且 分析流保留了这些数据的完整性，确保统计方法生成模型 具有生物学意义的生物。

Core F: NIC Summary/Abstract The overall goal of the PITT-ADRC is to perform and promote research that increases our understanding of: 1) the etiology and pathogenesis of Alzheimer's disease (AD), 2) the mechanisms underlying the cognitive and behavioral symptoms of AD, and 3) to develop strategies that will result in effective early diagnoses and treatments for AD and related dementias. The Neuroimaging Core (NIC) will support these Center-wide goals by developing and applying cutting edge neuroimaging technology to studies that are focused on early and presymptomatic stages of the AD spectrum. As the search for preclinical biomarkers continues, it is becoming increasingly clear that functional and structural brain imaging data may hold the key to identifying the earliest pathological manifestations of AD prior to any meaningful clinical change. The NIC will continue to develop and distribute technology for acquiring and interpreting brain functional and structural imaging data in the support of AD research. The NIC will advance the Center goals by supporting and promoting research that increases our understanding of the etiology and pathogenesis of AD and facilitates the development of new therapies and methods for monitoring therapeutic efficacy. The NIC maintains data sets of structural imaging on individuals enrolled through the Clinical Core, and we continue to work on the expansion of leading-edge analytic technologies, and novel radiotracer ligands measured with Positron Emission Tomography (PET) (i.e., PiB, AV-1451 and GTP-1). The work of the NIC will accelerate efforts to identify early and presymptomatic AD by identifying imaging biomarkers to monitor the natural and treated history of the disease. The curated, “trial-ready” participant database will allow PITT-ADRC researchers to track biomarker-based clinical progression and to identify risk and protective factors. This database will also uniquely position the PITT-ADRC to identify potential participants based on specific biomarker characteristics. Finally, the NIC’s focus on quality assurance will ensure that neuroimaging methods are generating data measuring what they purport to measure and that the analysis stream retains the integrity of these data, ensuring that the statistical methodologies generate model that are biologically meaningful.